Pump thrombosis is a devastating complication of left ventricular assist device implantation as it increases the risk of mortality and morbidity. Early and effective treatment is important to prevent the progression of the clot and to avoid the surgical need for pump exchange or heart transplant. The current strategies of intensifying anticoagulation therapy are not consistently effective and carry significant bleeding risks. Cangrelor is a new pharmacological agent that has been utilized as an antiplatelet agent in several cardiac procedures. In this case series, we describe the use of cangrelor for left ventricular assist device thrombosis in five patients. Cangrelor appears to be a potentially safe and effective alternative strategy.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Rao, Roopa; Anderson, Eve; Jones, Mark; Safiia, Muhamed; and Guglin, Maya
"Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis,"
The VAD Journal: Vol. 6(2)
Available at: https://digitalcommons.library.tmc.edu/vad/vol6/iss2/1